NeoDynamics AB (publ) - Quarterly report January-March 2019
First quarter 2019
- Revenue amounted to SEK 5.420 m (4.277 m). No sales have taken place during the period. Capitalized costs of SEK 5.418 m (4.277 m) are included in the revenue.
- Profit after tax amounted to SEK -4.134 m (-2.533 m).
- Earnings per share amounted to SEK -0.27 (-0.37).
- Equity ratio was 94 procent (65).
Significant events during the period
- On April 8-9 in Berlin, Dr. Marc Thill (Priv.-Doz. Dr. med.), Agaplesion Markus-Krankenhaus, presented the plans for the German multicenter study ("PULSE") for the biopsy of lymph nodes to 150 specialists. The study is being conducted by the German association for research in radiological gynecology, AWOGyn.
- The Breast Center at Karolinska University Hospital has evaluated NeoNavia and has been granted permission by the Swedish Ethical Review Authority to collect data on biopsies.
- The audit of our quality system has been completed and a new certificate according to the ISO 13485:2016 standard has been received.
Significant events after the end of the period
- Advance notice of a granted patent on our biopsy device was obtained from the US Patent and Trademark Office.
- Concept development of a biopsy clip/marker started with an American specialist to broaden the range of biopsy products to our target group.
Invitation to audiocast
The report will be presented in an audiocast today at 10.15 (CET). The audiocast is presented by CEO Anna Eriksrud and CFO Jörgen Vrenning. The audiocast may be followed::
Sound and pictures: https://tv.streamfabriken.com/neodynamics-q1-2019
Souind: Sverige: +46 8 566 427 06, UK +44 333 300 9030 USA +1 833 526 8383
CEO’s comments
Studies pave the way for successful launch
NeoDynamics’ strategy is to take our biopsy system NeoNavia for a commercial proof of concept by launching the new version in the Nordic countries, Germany and the UK. Later on, we will out license the product to a medical technology company with global sales or make a tech trade sell.
In the medical technology domain, it is possible to provide clear evidence of a product’s potential with a relatively small number of talented key account managers. If there is support from leading “KOL”, Key Opinion Leader centers from the very beginning, the impression made will be greater and the launch faster.
Our priorities are clear:
• We will document our new product for CE
approval and submit the application in the second half of 2019.
• We will submit a 510(k) application to the FDA.
• We will complete our clinical studies in 2020.
•We prepare ourselves for Chinese FDA
The focus during the first quarter has been on our clinical studies in Sweden, Germany and the UK, the aim of these being to support the launch of NeoNavia during 2020. The documentation of the product's applications will allow doctors to become familiar with the technology, and enable us to establish a presence at leading clinics. This will strengthen our brand, and meanwhile we will become known to both the healthcare system and the compensation system used by the healthcare system. We will hereby increase our chances of getting recommendations from the leading clinics.
The design for our German multicenter study (“PULSE”), which involves taking biopsies of the axillary lymph nodes, was presented to approximately 150 specialists at the German association for research in radiological gynecology AWOGyn’s meeting in Berlin in April. Our principal investigator Dr Marc Thill (Priv.-Doz. Dr. Med.) from Agaplesion Markus-Krankenhaus predicted during the presentation that the study will influence and simplify the biopsy procedure for German doctors and their breast cancer patients.
The Breast Center at Karolinska University Hospital got permission from the Ethics Review Board to collect data from its evaluation of NeoNavia in order to be able to publish the results of completed breast biopsies in a scientific journal. This will be a door opener for us and will confirm that the biopsy needle that we have developed works in the axilla and in the breast.
We recently started developing the concept for a “clip”, a biopsy marker, to be used by doctors in conjunction with biopsies to mark the site of the tumor. The use of a clip is standard in the US, and is becoming more common in Europe. The aim is to produce a product that is more visible during ultrasound than existing products on the market. In collaboration with a US specialist, we will develop a new biopsy marker that will complement our biopsy product portfolio.
The business is currently operating at a fast pace, with intriguing new features, and we are essentially following the plan that has been established. The feedback we receive from our customers is positive and encouraging. In the second half of this year, our development costs will decrease and there will be more focus on market preparations with NeoNavia. In this context, we are pleased to have received advance notice of the approved biopsy device patent from the US Patent and Trademark Office, since the market in the US is twice as large as that in Europe.
We are working actively to ensure that more people within the stock market get to know us and come to appreciate the company’s potential.
CEO Anna Eriksrud
Financial overview
First quarter 2019
During the period January-March 2019, the company developed according to plan, the main costs beings associated with product development, clinical studies and personnel. NeoDynamics applies a policy of capitalization of development costs to intangible assets, but not of personnel costs.
Revenue
During the period, the Company had no product sales. Capitalized costs accounted for SEK 5.418 m (4.277 m) of the reported revenues of SEK 5.420 m (4.277 m).
Earnings
Earnings before depreciation for the period amounted to SEK -4.031 m (-2.428 m). External costs increased to SEK 6,963 (5,412) and consisted mainly of costs relating to clinical studies and product development. Staff costs increased to SEK 2.411 m (1.283 m), partly as a result of the number of employees increasing from four to five. Profit for the year before tax and after tax amounted to SEK -4.134 m (-2.533 m).
Financial postition
At the end of the period, the equity ratio was 94 percent, compared with 90 percent at year-end. Shareholders’ equity amounted to SEK 70 429 m compared with SEK 26.706 m at year-end. Cash and cash equivalents amounted to SEK 15.329 m (SEK 25.654 m at year-end). Total assets amounted to SEK 74.750 m (SEK 82.639 m at year-end).
Capital requirements
The Board’s assessment is that the working capital requirement in 2019 will be met by using available cash and net proceeds from a planned new issue through a warrant program that may raise approximately SEK 24 m in new equity at the end of the year.
Seasonal variations
The company is in a period during which significant funds are being invested in the development of the NeoNavia biopsy system. In the second half of 2019 the CE submission of file will take place. Development costs are expected to decline during the second half of the year.
NeoDynamics shares
NeoDynamics shares have been listed on the Spotlight Stock Market since December 7, 2018. The short name of the share is “NEOD” and the ISIN code is SE0011563410. As of December 31, 2018, the total number of shares in issue was 15,303,520 (6,908,000).
Ownership
The table below shows shareholdings and the share of votes and capital for the 10 largest shareholders in NeoDynamics AB at the end of the first quarter.
| 1 | Boai NKY Medical Holdings Ltd, China | 4,922,544 | 32.17% |
| 2 | M2 Capital Management AB | 1,278,457 | 8.35% |
| 3 | Gryningskust Holding AB | 914,900 | 5.98% |
| 4 | Huasheng Fang | 768,290 | 5.02% |
| 5 | ADB Invest AB | 360,700 | 2.36% |
| 6 | Jörgen Vrenning | 356,054 | 2.33% |
| 7 | Rentability Sweden AB | 290,694 | 1.90% |
| 8 | Claes Pettersson | 242,834 | 1.59% |
| 9 | Humlan Fastighetsutveckling AB | 240,000 | 1.57% |
| 10 | Espander Life Science Partner AB | 200,000 | 1.31% |
Annual shareholder meeting
NeoDynamics’ Annual General Meeting will be held on May 23, 2019, at Scandic Foresta/Vinterträdgården, Lidingö, Sweden. The annual report is available on the company’s website (www.neodynamics.se.
Dividend
The Board of Directors and the CEO propose no dividend for the financial year 2018.
Financial calendar
Annual General Meeting May 23, 2019
Interim report (Jan-Jun) Aug 21, 2019
Interim report (Jan-Sept) Nov 21, 2019
Risks and uncertainties
A number of risk factors could have a negative impact on NeoDynamics AB’s operations. It is therefore important to consider any relevant risks in addition to the Company’s growth opportunities. For a detailed outline of the risks attributable to the Company and its shares, please refer to the prospectus published by the Board in October 2018.
Accounting principles
The year-end report has been prepared in accordance with the Annual Accounts Act and in accordance with the Swedish Accounting Standards Board’s general advice BFNAR 2012: 1 Annual Report and Consolidated Financial Statements (K3). For intangible assets, the activation model in the general council has been applied. The company’s assets and liabilities are stated at cost and nominal value, unless otherwise stated.
Review of the report
This report has not been reviewed by the company’s auditor.
First quarter report submitted
The Board of Directors and the CEO hereby certify that the quarterly report provides a true and fair view of NeoDynamics’ operations.
Lidingö May 21, 2019
Anna Eriksrud Ingrid Salén Carina Bolin
CEO Chairman of the board Board member
Claes Pettersson Jörgen Vrenning Xiaojun Xu
Board member Board member Board member
NeoDynamics AB, 559014-9117
For further information please contact
Anna Eriksrud, tel 0708 444966 or anna.eriksrud@neodynamics.se
Jörgen Vrenning, tel 0708-519648 or jorgen.vrenning@neodynamics.se
